Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 4 November 2021, 09:39 HKT/SGT
Share:
    

Source: Eisai
Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
For Early Alzheimer's Disease in Late-Breakers and Pipeline Updates at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference

TOKYO, Nov 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of data from the company's extensive Alzheimer's disease (AD) pipeline, including six oral presentations that will provide deeper insights into lecanemab's potential as a treatment for early AD. Eisai initiated a rolling submission of a Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, for the treatment of early AD, to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway in September 2021. The lecanemab data and additional research findings from Eisai's robust AD pipeline will be featured in 10 presentations, including five late breaker oral presentations, at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference, November 9-12, 2021, in Boston, Massachusetts and virtually.

"The findings Eisai will present at CTAD provide scientific insights into the potential role of lecanemab in the treatment of early Alzheimer's disease as well as the relationship between clearance of amyloid-beta plaque from the brain, changes in blood-based biomarkers and clinical outcomes," said Michael Irizarry, M.D., Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "We are working to advance lecanemab and our other targeted investigational compounds as quickly as possible in our commitment to bringing solutions to patients and their families."

The focus on AD has historically been on alleviating cognitive, functional, and behavioral symptoms, but there has been significant progress in understanding the biological mechanisms of the disease and Eisai's investigational pipeline aims to treat the range of underlying pathophysiology, including amyloid, tau and neurodegeneration.

"With lecanemab's rolling BLA submission to the FDA under the accelerated approval pathway, completion of enrollment of 1,795 patients in the confirmatory Phase 3 Clarity AD clinical trial, initiation of a lecanemab subcutaneous dosing Phase 1 study and the ongoing Phase 3 AHEAD 3-45 study in people with pre- clinical Alzheimer's disease, it is an exciting time for lecanemab and Eisai's AD franchise," said Ivan Cheung, Chairman, Eisai Inc., Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd. "We are optimistic about the promise lecanemab and other investigational compounds in our robust pipeline may have for people living with Alzheimer's disease."

For more information, visit https://www.eisai.com/news/2021/pdf/enews202182pdf.pdf.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Jan 20, 2022 08:56 HKT/SGT
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
Jan 19, 2022 16:36 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
Jan 19, 2022 09:06 HKT/SGT
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study
Jan 17, 2022 10:44 HKT/SGT
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
Jan 13, 2022 12:26 HKT/SGT
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health)
Jan 6, 2022 10:09 HKT/SGT
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
Dec 24, 2021 08:26 HKT/SGT
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
Dec 21, 2021 09:23 HKT/SGT
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States
Dec 20, 2021 12:35 HKT/SGT
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
Dec 6, 2021 11:30 HKT/SGT
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: